Kestra Medical Technologies (KMTS) Cash from Financing Activities (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Cash from Financing Activities data on file, last reported at -$185000.0 in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 100.09% year-over-year to -$185000.0 in Q2 2026; TTM through Apr 2026 was $147.1 million, a 55.46% decrease from a year earlier, with the FY2026 full-year figure at $147.1 million, down 55.46% from the prior year.
• Cash from Financing Activities for Q2 2026 stood at -$185000.0, down from $149.2 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for KMTS reached as high as $214.7 million in Q2 2025 and fell as low as -$1.9 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $54.4 million across 3 years, with a median of -$27000.0 in 2025.
• Across the five-year window, Cash from Financing Activities tumbled 101.61% in 2025 and surged 125463.03% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at -$575000.0 in 2024, then surged by 95.3% to -$27000.0 in 2025, then tumbled by 585.19% to -$185000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$185000.0 in Q2 2026, $149.2 million in Q1 2026, and -$27000.0 in Q4 2025.